J
Josef Hruska
Researcher at Novartis
Publications - 4
Citations - 284
Josef Hruska is an academic researcher from Novartis. The author has contributed to research in topics: Zoledronic acid & Osteoporosis. The author has an hindex of 2, co-authored 4 publications receiving 243 citations.
Papers
More filters
Journal ArticleDOI
Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis
Steven Boonen,Jean-Yves Reginster,Jean-Marc Kaufman,Kurt Lippuner,Jose R. Zanchetta,Bente L. Langdahl,René Rizzoli,Stanley Lipschitz,Hans Peter Dimai,Richard Witvrouw,Erik Fink Eriksen,Kim Brixen,Luis Russo,Frank Claessens,Philemon Papanastasiou,Oscar Antunez,Guoqin Su,Christina Bucci-Rechtweg,Josef Hruska,Elodie Incera,Dirk Vanderschueren,Eric S. Orwoll +21 more
TL;DR: Zoledronic acid treatment was associated with a significantly reduced risk of vertebral fracture among men with osteoporosis and results were similar in men with low serum levels of total testosterone.
Journal Article
Renal effects of treatment with zoledronic acid: results from the horizon-pft extension study
Journal Article
Efficacy of once-yearly zoledronic acid 5 mg in men with osteoporosis with different levels of serum total testosterone
Steven Boonen,Jean-Yves Reginster,Jean-Marc Kaufman,Kurt Lippuner,Jose R. Zanchetta,Bente L. Langdahl,René Rizzoli,Hans Peter Dimai,Erik Fink Eriksen,Kim Brixen,Oscar Antunez,Guoqin Su,Josef Hruska,Dirk Vanderschueren,Eric S. Orwoll +14 more